Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors

Overview

Background: Researchers want to study fluids and blood of people with cancer. The fluids are from the abdomen and around the lungs. Studying these might help researchers learn about the biology of cancer. This may lead to better ways to treat cancer. Objectives: To study the biology of cancer. Eligibility: Adults 18 and older with malignant solid tumors. Design: Participants will be screened with medical history, blood tests, and confirmation of diagnosis. Participants will have samples taken at regularly scheduled procedures. Fluids from the abdomen and/or lungs will be taken as part of the procedures. Blood will be taken separately. Participants may be asked to give more samples at future procedures.

Background: -Malignant ascites or pleural effusions are often seen in patients with solid tumor malignancies. -Malignant ascites is proinflammatory with many cytokines present and acts to promote tumor cell growth. -The cellular composition of malignant ascites consists of lymphocytes, macrophages and monocytes. -Serum monocytes and lymphocytes play a role in the native host anti-tumor immune mediated mechanisms. -A paracentesis or thoracentesis is often done for symptomatic relief from the malignant fluid collection. Primary Objective: -To obtain blood samples and ascites and pleural effusion samples from patients with solid tumor malignancies, with the intent of performing translational studies related to cancer. Eligibility: * Patients greater than or equal to 18 years of age. * Diagnosis of malignant solid tumor. * Patients must be able and willing to provide informed consent. Design: -We will collect approximately 200cc-5L ascites from patients that are undergoing a therapeutic paracentesis or thoracentesis. No thoracentesis or paracentesis will be performed solely for research purposes. -The fluid will be collected during the medical procedure and may be collected at more than one time point. -We will also collect 30ml of peripheral blood. This will be from patients who are being seen in follow up, consultation, or presenting for enrollment on a clinical trial.

Conditions